OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

News

10/29/2020

Leading Parkinson’s Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor

 

Read More

10/22/2020

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

 

Read More

10/15/2020

Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the Treatment of Parkinson’s Disease

 

Read More

10/8/2020

Newscope Capital (d/b/a Pharmather) Announces Listing on the Canadian Securities Exchange

 

Read More

    Archives

    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

    Categories

    All

    RSS Feed

Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT
Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2022.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.